Janney Montgomery Scott LLC decreased its stake in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 7.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 7,163 shares of the company’s stock after selling 553 shares during the period. Janney Montgomery Scott LLC’s holdings in DaVita were worth $593,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Quent Capital LLC grew its position in DaVita by 7.5% during the second quarter. Quent Capital LLC now owns 1,674 shares of the company’s stock worth $134,000 after buying an additional 117 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in DaVita by 2.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,505 shares of the company’s stock worth $440,000 after buying an additional 124 shares in the last quarter. Brinker Capital Investments LLC increased its holdings in DaVita by 0.6% in the 2nd quarter. Brinker Capital Investments LLC now owns 23,453 shares of the company’s stock valued at $1,875,000 after buying an additional 129 shares during the period. Captrust Financial Advisors raised its position in shares of DaVita by 3.7% in the 1st quarter. Captrust Financial Advisors now owns 3,860 shares of the company’s stock valued at $437,000 after buying an additional 139 shares in the last quarter. Finally, GHP Investment Advisors Inc. boosted its position in shares of DaVita by 0.3% during the 2nd quarter. GHP Investment Advisors Inc. now owns 46,865 shares of the company’s stock worth $3,747,000 after acquiring an additional 144 shares in the last quarter. 86.52% of the stock is owned by institutional investors.
DaVita Stock Up 1.0 %
Shares of NYSE DVA opened at $80.32 on Friday. DaVita Inc. has a 12-month low of $65.28 and a 12-month high of $124.81. The firm has a market cap of $7.24 billion, a PE ratio of 11.76, a P/E/G ratio of 1.45 and a beta of 0.96. The company’s fifty day simple moving average is $74.65 and its 200 day simple moving average is $82.19. The company has a quick ratio of 1.22, a current ratio of 1.26 and a debt-to-equity ratio of 12.63.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the company. TheStreet lowered DaVita from a “b-” rating to a “c+” rating in a research note on Tuesday, November 1st. Deutsche Bank Aktiengesellschaft cut DaVita from a “buy” rating to a “hold” rating and dropped their price target for the company from $97.00 to $72.00 in a research note on Tuesday, November 1st. Barclays dropped their target price on DaVita from $103.00 to $81.00 and set an “equal weight” rating for the company in a research report on Monday, October 31st. UBS Group cut DaVita from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $117.00 to $74.00 in a report on Monday, October 31st. Finally, StockNews.com upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, December 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and an average price target of $81.17.
Insiders Place Their Bets
In other DaVita news, Director John M. Nehra purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 1st. The shares were acquired at an average cost of $71.14 per share, for a total transaction of $355,700.00. Following the completion of the acquisition, the director now owns 15,000 shares of the company’s stock, valued at approximately $1,067,100. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.00% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.